HOME >> BIOLOGY >> NEWS
Symposium explores microbial forensics and the investigation of biocrimes

February 16, 2003--Denver, CO--September 11 and the events of October 2001 have focused attention on the threat posed by criminals that may use biological pathogens to do harm--and how to catch them. The massive investigation into the anthrax letters that caused more than 20 cases of rare, inhalation anthrax and at least 5 deaths blended public health and law enforcement strategies in an effort to stop the outbreak and trace the organism. Unfortunately, the perpetrator or perpetrators remain at large. Microbial Forensics: A Scientific Assessment, a symposium at the Annual Meeting of the American Association for the Advancement of Science (AAAS) in Denver, CO, will address the systems, methods and technologies required for the successful investigation of biocrimes that could be directed against individuals, institutions, livestock and crops.

The session on Sunday, February 16, 2:30-5:30 pm, will explore microbial forensics, the emerging discipline that combines principles of public health epidemiology and law enforcement to identify patterns in a disease outbreak, determine the pathogen involved, control its spread and trace the microorganism to its source--the perpetrator(s). Microbial forensics investigations require and use traditional investigative methodology, established molecular techniques and new, advanced methods that still may be under development. Since investigators must consider eventual prosecution and presentation of evidence in the courts, biocrime criminal investigations require careful controls and standards for validation and evaluation of technologies and the data they produce.

Speakers at the American Academy of Microbiology (AAM) sponsored session include organizer Abigail Salyers, Ph.D. ,University of Illinois, Urbana-Champaign, and past president of the American Society for Microbiology, who will provide an overview of microbial forensics. Bruce Budowle, Ph.D., of the F.B.I. will speak on Practical Implications of Microbial
'"/>

Contact: Andrea Lohse
alohse@asmusa.org
202-942-9292
American Society for Microbiology
16-Feb-2003


Page: 1 2

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
4. Health of worlds sea lions the focus of Wakefield Symposium
5. Chemical signals health of brain cells Symposium
6. Final Alert: 16th EORTC NCI AACR Symposium
7. 16th EORTC NCI AACR Symposium
8. Symposium to tackle questions of genetic engineering and biodiversity
9. Fostering Diversity in the Sciences Symposium
10. Annual Chemical Biology Symposium at Yale May 14, 2004
11. Symposium relates long-term ecological research to ecosystem management

Post Your Comments:
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... Many factors, both genetic and environmental, have been ... of schizophrenia. Some, such as a family history ... infection with Toxoplasma gondii , a parasite ... are still viewed with skepticism. , A new ... and epidemiology at the University of Pennsylvania,s School ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... Orlando, Florida (PRWEB) October 27, 2014 ... aims at reducing and eliminating several types of ... have not been achieved in over 30 years ... of Noah's Light Foundation, proves that one mom's ... was diagnosed just before Halloween trick-or-treating, and it’s ...
(Date:10/27/2014)... October 27, 2014 Investor-Edge has ... (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ), ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,483.72, up 0.69%, the Dow Jones ...
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
Breaking Biology Technology:Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
Cached News: